Valproate Use Beyond Bipolar Disorder

FDA-Approved and Guideline-Supported Indications

Valproate is a standard first-line antiepileptic drug for convulsive epilepsy, recommended alongside carbamazepine, phenobarbital, and phenytoin 1
For patients with intellectual disability and epilepsy, valproate or carbamazepine should be considered preferentially over phenytoin or phenobarbital due to lower risk of behavioral adverse effects 1
Monotherapy with valproate is appropriate for both partial onset and generalized seizures 1
The American Academy of Neurology recommends valproate as a first-line treatment for epilepsy, particularly generalized or mixed seizure types 1

Primary indications for valproate in non-bipolar patients include epilepsy, with standard therapeutic dosing targeting serum levels of 50-100 mcg/mL 1
For behavioral symptoms, individualized dosing with systematic 6-8 week trials at adequate doses is recommended before concluding ineffectiveness 2

Baseline assessment should include liver function tests, complete blood count, and pregnancy test in females, as well as documenting baseline weight due to valproate's association with weight gain 2
Serum drug levels, hepatic function, and hematological indices should be monitored every 3-6 months during maintenance therapy 2
For women of childbearing potential, valproate should be avoided if possible due to teratogenic risks, and folic acid supplementation is mandatory for those who must continue treatment 1

Valproic acid should be avoided in women with epilepsy who are pregnant or planning pregnancy, with folic acid supplementation mandatory for those who must continue treatment 1
In pediatric populations with epilepsy, carbamazepine may be preferentially offered over valproate for partial onset seizures 1
The American Academy of Neurology recommends considering discontinuation of valproate after 2 seizure-free years in patients with epilepsy, with decisions made considering clinical, social, and personal factors 1
Systematic trials of 6-8 weeks at adequate doses are required before concluding treatment failure for mood-related indications 2